cepi: CEPI Partners with Bharat Biotech Consortium, Sydney University and ExcellGene to Develop Variant-Proof SARS-CoV-2 Vaccine |  News from India

cepi: CEPI Partners with Bharat Biotech Consortium, Sydney University and ExcellGene to Develop Variant-Proof SARS-CoV-2 Vaccine | News from India

HYDERABAD: Vaccine manufacturer Bharat Biotech said on Tuesday that it has been selected as part of an international multidisciplinary consortium that includes the University of Sydney and ExcelGene SA of Switzerland that is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of a SARS-CoV-2-proof vaccine variant.
As part of the partnership, tCEPI will extend funding of up to $ 19.3 million to support the development of the variant-proof vaccine. CEPI will fund researchers to conduct activities including immunogen design, preclinical studies, manufacturing process development, and a Phase 1 clinical trial.
The latest funding award is awarded as part of CEPI’s $ 200 million program to promote the development of vaccines that provide broad protection against SARS-Cov-2 variants and other beta-coronaviruses.
CEPI funding will support the consortium in an effort to establish preclinical and clinical proof of concept for an adjuvanted subunit vaccine designed to provide broad protection against all known variants of SARS-CoV-2 of concern, as well as future variants of the virus that have no has yet to emerge, Bharat Biotech said.
According to Bharat Biotech, in this new vaccine project, modified trimeric spike immunogens will be produced in a robust and scalable process with high purity and low cost yield, based on a bioproduction approach that has provided significant amounts of therapeutic proteins to the world. .
“This strategy could also be used to enable rapid development of broadly protective vaccines against other betacoronaviruses, as well as vaccines against disease X, unknown pathogens with pandemic potential that will emerge in the future,” he said.
Commenting on the development, Richard Hatchett, CEO of CEPI, said, “As repeated waves of Covid-19 infection remind us, we will live alongside the virus for many years to come. The threat of an emerging new variant that could circumvent the protection of our current vaccines is real, so investing in research and development for variant-proof SARS-CoV-2 vaccines is a global health security imperative.
“Our partnership with Bharat Biotech, University of Sydney and ExcellGene will advance the development of a candidate vaccine for protection against future Covid-19 variants, potentially contributing to the long-term control of the virus,” he said.
The president and CEO of Bharat Biotech, Dr. Krishna Ella, said that although his company has successfully commercialized a universal vaccine against Covid-19 with Covaxin, and the current generation of vaccines is safe and effective against currently known variants, it is imperative to focus on innovation for epitope vaccines. , where a single vaccine can protect against all future variants.
“Our experience in product development and innovation, particularly with new adjuvants and platform technologies, will add to the strong partnership with CEPI, ExcellGene and the University of Sydney,” said Ella.
Professor James Triccas, of the Sydney Institute for Infectious Diseases, of the University of Sydney, said the university will provide a framework for preclinical evaluation of vaccine candidates, along with access to the Australian community of early stage clinical trials. world level.
Noting that ExcellGene’s technology platform for designing innovative proteins has been used in the past to identify and produce an antigen for an Ebola candidate vaccine, which has led to sterilization of immunity in preclinical challenge models, Dr. Maria J Wurm, CEO of ExcellGene, said for the current Covid -19 project the company is using similar approaches to generate numerous antigenic preparations derived from spike protein variants of SARS-CoV-2, ultimately focusing on the most promising antigen for vaccine purposes.

.

Leave a Comment

Your email address will not be published.